LONG-TERM OUTCOMES OF LEDIPASVIR/SOFOSBUVIR (LDV/ SOF) FOR THE TREATMENT OF CHRONIC HEPATITIS C INFECTED (HCV) GENOTYPE 1 PATIENTS IN THE UK

被引：1
|
作者：
Guerra, I [1 ]
Marie, L. [2 ]
Cure, S. [1 ]
机构：
[1] OptumInsight, Uxbridge, Middx, England
[2] OptumInsight, Nanterre, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2507
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN66
引用
收藏
页码：A675 / A675
页数：1
相关论文
共 50 条
  • [21] Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in genotype 1 HCV-infected treatment-naive patients without cirrhosis with HIV co-infection and HCV RNA<6 million
    Ain, D.
    Wolfe, P.
    Weissman, M.
    Huezo, M.
    Cabrera, E.
    Hernandez, N.
    Tran, L.
    Ruane, P.
    Vu, V.
    Reeves, J.
    Jackson, A.
    [J]. HIV MEDICINE, 2016, 17 : 36 - 37
  • [22] Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4
    Marascio, Nadia
    Mazzitelli, Maria
    Pavia, Grazia
    Giancotti, Aida
    Barreca, Giorgio Settimo
    Costa, Chiara
    Pisani, Vincenzo
    Greco, Giuseppe
    Serapide, Francesca
    Trecarichi, Enrico Maria
    Casalinuovo, Francesco
    Liberto, Maria Carla
    Matera, Giovanni
    Torti, Carlo
    [J]. CELLS, 2019, 8 (05)
  • [23] Treatment of adolescents genotype 4 chronic HCV infected patients with Ledipasvir/Sofosbuvir combination: A real world experience
    Khayat, H. E.
    Kamal, I.
    El-Sayed, M. H.
    Ayoub, H.
    Shabrawy, M. E.
    Rizk, A.
    Yehia, R.
    Maher, M.
    Fouad, Y.
    Attia, D.
    [J]. JOURNAL OF HEPATOLOGY, 2018, 68 : S327 - S327
  • [24] Treatment of Chronic Hepatitis C Genotype 3 With Ledipasvir and Sofosbuvir: An Observational Study
    Dar, Gulzar A.
    Yattoo, Ghulam N.
    Gulzar, Ghulam M.
    Sodhi, Jaswinder S.
    Gorka, Suresh
    Laway, Mushtaq A.
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2021, 11 (02) : 227 - 231
  • [25] Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1
    Kumari, Radhika
    Nguyen, Mindie H.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (05) : 739 - 748
  • [26] REALWORLD EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR (LDV/SOF) IN TREATMENT-EXPERIENCED CIRRHOTIC GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C: A COMPARATIVE ANALYSIS OF GILEAD SPONSORED TRIALS WITH 4 REAL-WORLD COHORTS
    Curry, M.
    Modi, A. A.
    Pungpapong, S.
    Leise, M.
    Aqel, B.
    Llewellyn, J.
    Williams, L. A.
    Natha, M.
    Brainard, D. M.
    Kreter, B.
    Kholi, A.
    Wyles, D.
    Lee, Y.
    Reddy, R.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S797 - S797
  • [27] HIGH THERAPEUTIC EFFICIENCY WITH LEDIPASVIR/SOFOSBUVIR FOR THE TREATMENT OF GENOTYPE 1 CHRONIC HEPATITIS C IN PORTUGAL
    Ferreira, D.
    Felix, J.
    Almeida, J.
    Mota, M.
    Afonso Silva, M.
    Silva, P.
    Vandewalle, B.
    Velosa, J.
    Marinho, R.
    Aldir, I
    Carvalho, A.
    Valente, C.
    Macedog, G.
    Sarmento e Castro, R.
    Pedroto, I
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A578 - A578
  • [28] The Impact of Concomitant Acid Reducing Therapy (ART) on Sustained Virologic Response (SVR-12) Among Genotype 1 Infected Chronic Hepatitis C (CHC) Patients Treated with Ledipasvir/Sofosbuvir (LDV/SOF) With or Without Ribavirin
    Spoutz, Patrick
    Schaefer, Monica
    Pandya, Prashant K.
    Patterson, Mark
    [J]. HEPATOLOGY, 2016, 64 : 477A - 478A
  • [29] LEDIPASVIR (LDV) AND SOFOSBUVIR (SOF) COMBINATION IMPROVES PATIENT-REPORTED OUTCOMES (PRO) DURING TREATMENT OF CHRONIC HEPATITIS C (CH-C) PATIENTS: RESULTS FROM THE ION-1 CLINICAL TRIAL
    Younossi, Z.
    Stepanova, M.
    Marcellin, P.
    Afdhal, N.
    Nader, F.
    Hunt, S.
    [J]. JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S536 - S537
  • [30] Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia
    Younossi, Z. M.
    Chan, H. L. Y.
    Dan, Y. Y.
    Lee, M. H.
    Lim, Y. -S.
    Kruger, E.
    Tan, S. C.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2018, 25 (03) : 228 - 235
12345